Bank of England, AstraZeneca, Watches of Switzerland: Thursday ahead
AstraZeneca and Watches of Switzerland will be in focus ahead of the Bank of Englands rate decision on Thursday. AstraZeneca…
71,710$
0,83%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid:
Ask:
Nachrichten zur Astrazeneca PLC (Spons. ADRs) Aktie
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress…
CHMP Gives Nod to Expanded Use of J&Js Rybrevant & AZNs Imfinzi
The CHMP recommends approval for JNJs subcutaneous formulation of Rybrevant in NSCLC and AstraZenecas Imfinzi in limited-stage small-cell lung cancer.…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Total Voting Rights
3 February 2025
Transparency Directive
Voting rights and capital
The following notification is made in accordance with the UK Financial Conduct Authoritys Disclosure…
Imfinzi recommended for EU approval for LS-SCLC
3 February 2025
Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung…
AstraZeneca ditches £450m investment in UK plant
The drugs giant blames "protracted" talks with the government as well as differences over funding.…
Vodafone, AstraZeneca, Amazon and Santander in busy week ahead
Vodafone, Santander, GSK, AstraZeneca and Diageo are among those teeing up a busy week ahead. Vodafone, as its £15 billion merger…
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AstraZeneca, IIPR, Block, and Crocs and Encourages Investors to Contact the Firm
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…
Enhertu approved in US for breast cancer post ET
28 January 2025
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following…